A Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia

• Status: Completed
• Trial end date: 2009-02-12
• Target enrollment: 0
• Participant gender: All

Summary

This study was performed to evaluate the local and systemic safety profile and the analgesic efficacy of long-term treatment with lidocaine 5% medicated plaster (Lido-Patch).

The study was an open-label, multi-center, multiple-dose, Phase III study and comprised a main and an extension period. 161 participants who completed treatment in KF10004/01 (NCT03745404) and 98 newly recruited participants were enrolled.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Grünenthal GmbH
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• Adult participants, male and female, with a minimum age of 50 years at screening.

• Participants who had postherpetic neuralgia (PHN) for at least 3 months after healing of a herpes zoster skin rash.

• Only for patients who had not participated in the KF10004/01 (NCT03745404) study: Pain score of at least 4, based on an 11-point numerical rating scale (NRS) (scale of 0-10), at the screening visit. The pain assessment is the participant's recall of the pain intensity since the previous week.

• Written informed consent given.

Exclusion Criteria:

• Participation in another study of investigational drugs or devices parallel to, or less than 30 days before screening, or previous participation in this study, except previous participation in the KF10004/01 study.

• Known to or suspected of not being able to comply with the study protocol.

• Any clinically significant condition that would, in the investigator's opinion, preclude study participation for instance alcohol, medication or drug dependency, neurotic personality, psychiatric illness, epilepsy or suicide risk.

• Pregnancy or nursing mother.

• Woman in childbearing age without satisfactory contraception.

• Hypersensitivity to lidocaine or amide-type local anesthetic drugs.

• Active herpes zoster lesion or dermatitis of any origin at the affected site with PHN.

• Evidence of another cause for pain in the area affected by herpes zoster in addition to PHN, such as lumbar radiculopathy, surgery or trauma, if this could confound assessment or self-evaluation of the pain due to PHN.

• Participants who had neurological ablation by block or neurosurgical intervention for control of pain in PHN.

• Participants using topically applied analgesic compounds on the PHN affected area.

• Presence of other severe pain that could confound assessment or self-evaluation of the pain due to PHN.

• Participants with severe hepatic disorder and/or alanine or aspartate aminotransferase equal to or above 3-fold the upper limit of normal (ULN).

• Participants with severe renal disorder and/or increased serum creatinine equal to or above 1.5-fold the upper limit of normal (ULN).

• Participants who are undergoing active treatment for cancer, are known to be infected with the human immunodeficiency virus (HIV), or being acutely and intensively immunosuppressed following transplantation.